{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-030764","form_type":"8-K","ticker":"MNPR","cik":"0001645469","company_name":"Monopar Therapeutics","filed_at":"2024-10-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.088327+00:00","generated_at":"2026-05-30T19:16:51.990940+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Monopar initiates Phase 1a trial of MNPR-101-Lu radiopharmaceutical therapy in advanced cancers","bullets":["Phase 1a open-label dose-escalation study of MNPR-101-Lu in solid tumors now recruiting.","First site activated: Melbourne Theranostic Innovation Centre in Australia.","Trial open only to patients in ongoing MNPR-101-Zr Phase 1 imaging/dosimetry trial.","MNPR-101 targets uPAR, expressed in pancreatic, breast, colorectal, ovarian, and bladder cancers.","CEO says trial launched months ahead of original schedule."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-030764","json":"https://secwatch.observer/filing/0001437749-24-030764.json","markdown":"https://secwatch.observer/filing/0001437749-24-030764.md","text":"https://secwatch.observer/filing/0001437749-24-030764.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645469/000143774924030764/0001437749-24-030764-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645469/000143774924030764/mnpr20241004_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T19:16:51.990940+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}